Therefore, this study aimed to epidemiologically investigate the factors associated with ALT levels >30 U/L and the potential risk factors for liver fibrosis, including genetic polymorphisms, in a general population cohort of patients with MASLD. The gene discussed is GPT; the disease is Hepatic fibrosis.